Gilberto Lopes: Few of the positive trials we have data for in lung cancer from ASCO24

Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X:       .

“Alright!

ASCO abstracts are out. Most plenary and oral are LBAs so not out yet. Let’s check a few of the positive trials we have data for in lung cancer.

 HARMONi-A – ivonescimab, an anti-PD-1/VEGF bispecific antibody, added to chemo vs chemo alone after EGFR TKI shows clinically relevant improvement in PFS!

322 patients randomized. 85%+ has 3rd gen – HR 0.46 [0.34, 0.62], P < 0.0001. Clearly positive.

New options for treatment are welcome. No OS data yet. Trial from China. Shouldn’t matter. But that has created challenges for approval in the US recently.”

Source: Gilberto Lopes/X